https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-03-01 / Scand. J. Immunol. 2011 Mar;73(3):222-33
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-03-01 / Scand. J. Immunol. 2011 Mar;73(3):222-332011-03-01 00:00:002019-02-15 08:49:20Changes in peripheral blood level of regulatory T cells in patients with malignant melanoma during treatment with dendritic cell vaccination and low-dose IL-2
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-02-19 / J. Neurooncol. 2011 Sep;104(3):659-67
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-02-19 / J. Neurooncol. 2011 Sep;104(3):659-672011-02-19 00:00:002019-02-15 08:46:14Exosome-loaded dendritic cells elicit tumor-specific CD8+ cytotoxic T cells in patients with glioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-02-10 / Gene Ther. 2011 Jun;18(6):584-93
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-02-10 / Gene Ther. 2011 Jun;18(6):584-932011-02-10 00:00:002019-02-15 08:49:19Phase I/II trial of a dendritic cell vaccine transfected with DNA encoding melan A and gp100 for patients with metastatic melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-02-09 / Cancer Res. 2011 Apr;71(7):2497-506
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-02-09 / Cancer Res. 2011 Apr;71(7):2497-5062011-02-09 00:00:002019-02-15 08:51:29IL-15 and type I interferon are required for activation of tumoricidal NK cells by virus-infected dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-02-03 / Clin. Cancer Res. 2011 Apr;17(8):2474-83
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-02-03 / Clin. Cancer Res. 2011 Apr;17(8):2474-832011-02-03 00:00:002019-02-15 08:48:16Heat-shock induction of tumor-derived danger signals mediates rapid monocyte differentiation into clinically effective dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-02-01 / J. Immunol. 2011 Feb;186(3):1325-31
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-02-01 / J. Immunol. 2011 Feb;186(3):1325-312011-02-01 00:00:002019-02-15 08:40:08Recent developments in cancer vaccines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-02-01 / Zhongguo Dang Dai Er Ke Za Zhi 2011 Feb;13(2):149-52
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-02-01 / Zhongguo Dang Dai Er Ke Za Zhi 2011 Feb;13(2):149-522011-02-01 00:00:002011-02-01 00:00:00[Roles of Newcastle disease virus in human acute monocytic leukemia in vitro and in vivo]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-01-28 / Expert Opin Biol Ther 2011 Apr;11(4):441-5
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-01-28 / Expert Opin Biol Ther 2011 Apr;11(4):441-52011-01-28 00:00:002019-02-15 08:52:18Dendritic cell vaccination against ovarian cancer–tipping the Treg/TH17 balance to therapeutic advantage?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-01-18 / Am. J. Reprod. Immunol. 2011 Jun;65(6):597-609
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-01-18 / Am. J. Reprod. Immunol. 2011 Jun;65(6):597-6092011-01-18 00:00:002019-02-15 08:40:09Enhanced stimulation of anti-ovarian cancer CD8(+) T cells by dendritic cells loaded with nanoparticle encapsulated tumor antigen
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-01-18 / Mol. Ther. 2011 Apr;19(4):797-804
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-01-18 / Mol. Ther. 2011 Apr;19(4):797-8042011-01-18 00:00:002011-01-18 00:00:00Oncolytic virus-initiated protective immunity against prostate cancer
